The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.
Judy-Anne W. Chapman
No relevant relationships to disclose
Lois E. Shepherd
No relevant relationships to disclose
James N. Ingle
No relevant relationships to disclose
Hyman Bernard Muss
No relevant relationships to disclose
Kathleen I. Pritchard
No relevant relationships to disclose
Karen A. Gelmon
No relevant relationships to disclose
Timothy Joseph Whelan
No relevant relationships to disclose
Catherine Elliott
No relevant relationships to disclose
Paul E. Goss
No relevant relationships to disclose